NEW YORK – Decipher BioSciences said last week that its Decipher Bladder cancer subtyping platform is able to predict which patients derive the most clinical benefit from neoadjuvant treatment with PD-1 inhibitor pembrolizumab (Merck's Keytruda).
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.